Tevogen Bio to Host AI and Healthcare Economics Panels at J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel Discussions "AI In Biopharma: Next Frontier of Medical Innovation" and "Pioneering the Economics of Health

WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Time (PST): 2:00 PM - 2:30 PM - AI in Biopharma: Next Frontier of Medical Innovation Panelists: Dr. David Rhew - Global Chief Medical Officer and VP of Healthcare, Microsoft (Nasdaq: MSFT) Dr. Sean Tunis - Principal, Rubix Health Mittul Mehta - Chief Information Officer and Head of Tevogen.AI, Tevogen Bio 2:30 pm - 3:15 pm - Afternoon Coffee Break 3:15 PM - 4:00 PM - Pioneering the Economics of Health: Balancing Access and Outcomes Victor Sordillo - MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio Peter Ehrhardt - Senior Partner at Simon-Kucher & Partners Dr. Poonam Alaigh - Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health Dr. Sean Tunis - Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures Dr. Ryan Saadi - Founder and CEO, Tevogen Bio 4:00 PM - 6:00 PM - Reception and Cocktails For inquiries regarding additional event details, please contact [email protected]. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Tevogen Bio to Host Panel Discussions AI In Biopharma, Next Frontier of Medical Innovation and Pioneering the Economics of Health, Balancing Access and Outcomes During J.P. Morgan Healthcare Conference

- Chief Information Officer and Head of Tevogen.AI, Tevogen Bio Dr. Poonam Alaigh - Former Acting Under Secretary for Health, ; Former Commissioner, Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Tevogen Bio to Host Panel Discussions AI In Biopharma: Next Frontier of Medical Innovation and Pioneering the Economics of Health: Balancing Access and Outcomes During J.P. Morgan Healthca By Investing.com

WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (Tevogen or Tevogen Bio Holdings Inc.) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. 3:15 PM " 4:00 PM " Pioneering the Economics of Health: Balancing Access and Outcomes Victor Sordillo " MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio Peter Ehrhardt " Senior Partner at Simon-Kucher & Partners Dr. Poonam Alaigh " Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health Dr. Sean Tunis - Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures Dr. Ryan Saadi " Founder and CEO, Tevogen Bio 4:00 PM " 6:00 PM " Reception and Cocktails For inquiries regarding additional event details, please contact [email protected]. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Tevogen Bio to Host Panel Discussions "AI In Biopharma: Next Frontier of Medical Innovation" and "Pioneering the Economics of Health: Balancing Access and Outcomes" During J.P. Morgan Healthcare Conference - Microsoft (NASDAQ:MSFT), Tevogen Bio Holdings (NASDAQ:TVGN)

The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs.Panelists to include David Rhew (Global Chief Medical Officer and VP of Healthcare, Microsoft), Sean Tunis (Principal, Rubix Health), Peter Ehrhardt (Senior Partner, Simon-Kucher), and Poonam Alaigh (Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs). WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") TVGN, will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Event Details Date: Monday, January 13, 2025 Location: Marines' Memorial Club & Hotel, 609 Sutter St., San Francisco, CA 94102 Time (PST): 2:00 PM - 2:30 PM - AI in Biopharma: Next Frontier of Medical Innovation Panelists: Dr. David Rhew - Global Chief Medical Officer and VP of Healthcare, Microsoft MSFT Dr. Sean Tunis - Principal, Rubix Health Mittul Mehta - Chief Information Officer and Head of Tevogen.AI, Tevogen Bio 2:30 pm - 3:15 pm - Afternoon Coffee Break 3:15 PM - 4:00 PM - Pioneering the Economics of Health: Balancing Access and Outcomes Victor Sordillo - MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio Peter Ehrhardt - Senior Partner at Simon-Kucher & Partners Dr. Poonam Alaigh - Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health Dr. Sean Tunis - Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures Dr. Ryan Saadi - Founder and CEO, Tevogen Bio 4:00 PM - 6:00 PM - Reception and Cocktails For inquiries regarding additional event details, please contact [email protected]. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 [email protected] MSFTMicrosoft Corp$439.500.04%Overview Rating:Good62.5%Technicals Analysis1000100Financials Analysis400100WatchlistOverviewTVGNTevogen Bio Holdings Inc$1.03-3.73%TVGNWTevogen Bio Holdings Inc$0.05003.73%Market News and Data brought to you by Benzinga APIs